Please login to the form below

Not currently logged in
Email:
Password:

DPP-4 inhibitor

This page shows the latest DPP-4 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Novo’s diabetes pill defeats Merck’s Januvia in trial

Novo’s diabetes pill defeats Merck’s Januvia in trial

Comparing oral semaglutide to Merck &Co’s DPP-4 inhibitor Januvia (sitagliptin), PIONEER 7 investigated the efficacy and safety of the GLP-1 inhibitor in people with type 2 diabetes. ... PIONEER 4 saw the enrolment of 711 people with type 2 diabetes

Latest news

  • FDA rejects AZ's diabetes combination FDA rejects AZ's diabetes combination

    The combination of DPP-4 inhibitor saxagliptin - sold by AZ as Onglyza - and SGLT2 inhibitor dapagliflozin (marketed as Farxiga/Forixiga) is considered to be a key component of the company's ... DPP-4 inhibitors are already widely used in diabetes and

  • Merck gets first OK for once-weekly DPP-4 inhibitor Merck gets first OK for once-weekly DPP-4 inhibitor

    Merck gets first OK for once-weekly DPP-4 inhibitor. Marizev approved in Japan. ... That includes Merck's Januvia (sitagliptin), which is heading the DPP-4 inhibitor market with sales of almost $4bn last year.

  • Jardiance survival data wows diabetes conference Jardiance survival data wows diabetes conference

    Overall, the findings give Lilly and Boehringer a lift versus their rivals in oral type 2 diabetes therapy, as Merck &Co's DPP-4 inhibitor Januvia (sitagliptin) was shown in the

  • FDA clears Jardiance combo for type 2 diabetes FDA clears Jardiance combo for type 2 diabetes

    While their metformin combination lagged behind rivals, Boehringer and Lilly were the first to get approval in the US for a combination of an SGLT2 inhibitor with a DPP-4 inhibitor, ... Tanabe. A combination of Pfizer's developmental SGLT2 inhibitor

  • Boehringer returns to growth in first half Boehringer returns to growth in first half

    DPP-4 inhibitor Trajenta competes head-to-head with a number of other drugs in the class, including Novo Nordisk's which also grew 22% to reach 8.4bn Danish krone

More from news
Approximately 1 fully matching, plus 59 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives

  • Interview: Allan Hillgrove, Boehringer Interview: Allan Hillgrove, Boehringer

    Boehringer's interest in the area is a relatively recent one and is focused on its major partnership with Lilly, which so far has produced Trajenta – a DPP-4 inhibitor for

  • Pharma deals during April 2013 Pharma deals during April 2013

    The deal with AZ, in oncology, follows a preclinical feasibility study on an undisclosed AZ kinase inhibitor. ... standalone product and in combination with other drugs, including Januvia (Merck's blockbuster DPP-4 inhibitor) and metformin.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics